The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
Status:
Terminated
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, randomized, double-blind, placebo-controlled, phase 3 study of
MDX (1400 mg daily) for 10 weeks compared with placebo in adults with ADHD.
The study will be comprised of Screening, Washout (if required), Treatment (total of 10
weeks) and Follow-up periods. Approximately 750 patients will be enrolled and undergo initial
eligibility assessments.